|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
7
|
Resverlogix Corp.
|
Mar 26, 2020 01:37PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 26, 2020 04:11PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
3
|
Resverlogix Corp.
|
Mar 24, 2020 05:40PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
1
|
Resverlogix Corp.
|
Mar 24, 2020 05:41PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
6
|
Resverlogix Corp.
|
Mar 24, 2020 06:08PM
|
|
Re: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
|
1
|
Resverlogix Corp.
|
Jun 21, 2023 08:01AM
|
|
Re: Resverlogix Announces One-Year Extension of Debenture
|
3
|
Resverlogix Corp.
|
Apr 19, 2022 07:05PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call...
|
1
|
Resverlogix Corp.
|
Jun 06, 2020 02:18AM
|
|
Re: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on
|
4
|
Resverlogix Corp.
|
Jun 07, 2020 11:08AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
8
|
Resverlogix Corp.
|
Dec 22, 2020 08:41AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
2
|
Resverlogix Corp.
|
Dec 22, 2020 11:58AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 12:26PM
|
|
Re: Resverlogix Announces Annual and Special Meeting of Shareholders
|
2
|
Resverlogix Corp.
|
Aug 23, 2019 08:58AM
|
|
Re: Reminds me of.......
|
5
|
Resverlogix Corp.
|
Jun 25, 2019 09:45AM
|
|
Re: Recent rise in SP...
|
5
|
Resverlogix Corp.
|
Sep 28, 2020 11:40AM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
2
|
Resverlogix Corp.
|
Jun 14, 2019 09:23AM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
1
|
Resverlogix Corp.
|
Jun 14, 2019 01:52PM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
|
Resverlogix Corp.
|
Jun 14, 2019 03:14PM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
1
|
Resverlogix Corp.
|
Jun 14, 2019 05:55PM
|
|
Re: RAAS Inhibitors in Patients with Covid-19
|
1
|
Resverlogix Corp.
|
Mar 31, 2020 12:22PM
|
